Amazon: Can Google, Amazon take on pharma’s mantle? Biotech giant Roche’s founders weigh in on the scenario.


From left, Jörg Duschmalé, member of board, Roche; André Hoffmann, Vice chairman of the board of directors, Roche. image courtesy: Roche.

Synopsis

Powered by the highest research spending in the industry, the world’s largest biotechnology company has built an array of first-in-class, industry-leading blockbusters. Besides, it keeps filling the revenue void left by patent expirations. André Hoffmann and Jörg Duschmalé, part of Roche’s founding family and board, share their thoughts on research, data, ownership, and management strategy.

A deadly cholera pandemic in 1896 triggered a scientific pursuit that created the world’s biggest biotechnology company, Roche. After an epochal journey of 125 years, Roche notched up sales of USD65 billion and a net income of USD15.4 billion last year. Although Roche may not be a household name in India, it has earned an enviable spot in the global pharmaceutical landscape. Over the years, the company has built an array of first-in-class,

  • FONT SIZE
  • SAVE
  • PRINT
  • COMMENT

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise



Source link

Leave a Comment